Abstract
Increasing evidence is being reported regarding the hypothesis that several proinflammatory and anti-inflammatory cytokines may promote tumor progression and affect the host antitumor response. However, the manner in which a local cytokine network operates in tumor development remains unclear. We reviewed the literature to examine the consequences of novel insights into inflammatory cytokines associated with gastric cancer progression. The Medline and EMBASE databases were searched for publications regarding the role of inflammatory cytokines in the development of gastric cancer. A number of studies have suggested that several proinflammatory and anti-inflammatory cytokines promote tumor progression through the direct activation of nuclear factor-κB (NF-κB) and the upregulation of angiogenesis and adhesion molecules. Furthermore, these processes suppress host antitumor immunity, leading to tumor progression and metastasis. In patients with advanced gastric cancer, most cytokines that enhance or suppress host antitumor immunity appear to have elevated serum and local expression levels. The net cytokine environment fluctuates at various stages of tumor development. In conclusion, a more detailed understanding of the differential roles of malignant cell-derived and hostderived cytokines at different stages of the malignant process could, consequently, open new avenues for the manipulation of cytokine expression and function in cancer immunotherapy for gastric cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Parkin DM. International variation. Oncogene 2004;23:6329–6340.
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1–241.
Crusius JB, Canzian F, Capella G, Pena AS, Pera G, Sala N, et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European Prospective Investigation Into Cancer and Nutrition (EPIC-EURGAST). Ann Oncol 2008;19:1894–1902.
Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249–260.
Hamajima N, Naito M, Kondo T, Goto Y. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 2006;97:1129–1138.
Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 2007;28:118–123.
Starzynska T, Ferenc K, Wex T, Kahne T, Lubinski J, Lawniczak M, et al. The association between the interleukin-1 polymorphisms and gastric cancer risk depends on the family history of gastric carcinoma in the study population. Am J Gastroenterol 2006;101:248–254.
Paul WE. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell 1989, 57:521–524.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275–293.
Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16:38–52.
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117:1175–1183.
Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527–5536.
Sun CF, Hsieh YY, Ngan KW, Wang WT. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood. Ann Clin Lab Sci 2001;31:171–178.
Chen G, Zhang FJ, Gong M, Yan M. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B 2007;8:560–565.
Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Impact of postoperative infection on long-term survival after potentially curative resection for gastric cancer. Ann Surg Oncol 2009;16:311–318.
Ozaki M, Todo S. Surgical stress and tumor behavior: impact of ischemia-reperfusion and hepatic resection on tumor progression. Liver Transpl 2007;13:1623–1626.
Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, et al. Ischemiareperfusion of small liver remnant promotes liver tumor growth and metastases-activation of cell invasion and migration pathways. Liver Transpl 2007;13:1669–1677.
Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
Gianfagna F, De Feo E, van Duijn CM, Ricciardi G, Boccia S. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 2008;9:361–374.
Gorouhi F, Islami F, Bahrami H, Kamangar F. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008;98:1443–1451.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361–371.
Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005;16:35–53.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184–190.
Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987;329:630–632.
Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 2004;21:39–47.
Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett 1995;95:207–212.
Wu CW, Chi CW, Hsieh MC, Chao MF, Lui WY, P’Eng FK. Serum tumor necrosis factor in patients with gastric cancer. Anticancer Res 1998;18:1597–1599.
Forones NM, Mandowsky SV, Lourenco LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 2001;48:1199–1201.
Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, et al. Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. J Surg Res 2008;148:197–204.
Furuya Y, Ichikura T, Mochizuki H, Shinomiya N. Relationship between interleukin-1-alpha concentration in tumors and cell growth in gastric cancer, determined using flow cytometry. Gastric Cancer 2000;3:86–90.
Uefuji K, Ichikura T, Mochizuki H. Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: a possible role in tumor progression. Anticancer Res 2005;25:3225–3230.
Tomimatsu S, Ichikura T, Mochizuki H. Significant correlation between expression of interleukin-1alpha and liver metastasis in gastric carcinoma. Cancer 2001;91:1272–1276.
Furuya Y, Ichikura T, Mochizuki H. Interleukin-1alpha concentration in tumors as a risk factor for liver metastasis in gastric cancer. Surg Today 1999;29:288–289.
Beales IL. Effect of interlukin-1beta on proliferation of gastric epithelial cells in culture. BMC Gastroenterol 2002;2:7–15.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398–402.
Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk-a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1920–1928.
Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastrooesophageal cancer. Br J Cancer 2006;95:1568–1575.
Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E. Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 1997;88:953–958.
Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003;22:7809–7818.
Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8:124–131.
Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009;12:95–100.
Sugai H, Kono K, Takahashi A, Ichihara F, Kawaida H, Fujii H, et al. Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer. J Surg Res 2004;116:277–287.
Morisaki T, Katano M, Ikubo A, Anan K, Nakamura M, Nakamura K, et al. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol 1996;63:234–239.
Sakamoto T, Saito H, Tatebe S, Tsujitani S, Ozaki M, Ito H, et al. Interleukin-10 expression significantly correlates with minor CD8+ T-cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 2006;118:1909–1914.
De Vita F, Orditura M, Galizia G, Romano C, Infusino S, Auriemma A, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 1999;86:1936–1943.
Majima T, Ichikura T, Seki S, Takayama E, Hiraide H, Mochizuki H. Interleukin-10 and interferon-gamma levels within the peritoneal cavity of patients with gastric cancer. J Surg Oncol 2001;78:124–130.
Szaflarska A, Szczepanik A, Siedlar M, Czupryna A, Sierzega M, Popiela T, et al. Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res 2009;29:5005–5012.
Majima T, Ichikura T, Seki S, Takayama E, Matsumoto A, Kawabata T, et al. The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. Anticancer Res 2002;22:1193–1199.
Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996;104:1–5.
Hatanaka H, Abe Y, Naruke M, Tokunaga T, Oshika Y, Kawakami T, et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/TIE2 networks in nonsmall cell lung cancer. Clin Cancer Res 2001;7:1287–1292.
Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495–521.
Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 2002;34:416–420.
Murakami S, Okubo K, Tsuji Y, Sakata H, Hamada S, Hirayama R. Serum interleukin-12 levels in patients with gastric cancer. Surg Today 2004;34:1014–1019.
Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989;57:590–595.
Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 2007;4:329–335.
Majima T, Ichikura T, Chochi K, Kawabata T, Tsujimoto H, Sugasawa H, et al. Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer 2006;118:388–395.
Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 2001;92:2050–2055.
Ye ZB, Ma T, Li H, Jin XL, Xu HM. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 2007;13:1747–1751.
Chen W, Wahl SM. TGF-beta: the missing link in CD4 + CD25 + regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev 2003;14:85–89.
Kawaida H, Kono K, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151–157.
Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007;95:123–128.
Yanagihara K, Tsumuraya M. Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992;52:4042–4045.
Fu H, Hu Z, Wen J, Wang K, Liu Y. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai) 2009;41:648–656.
Inoue T, Chung YS, Yashiro M, Nishimura S, Hasuma T, Otani S, et al. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 1997;88:152–159.
Komuro A, Yashiro M, Iwata C, Morishita Y, Johansson E, Matsumoto Y, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. J Natl Cancer Inst 2009;101:592–604.
Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999;17:607–614.
Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostic factors and patient survival. J Surg Res 2007;139:182–188.
Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-beta1 is signifi- cantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455–1462.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064–1071.
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–612.
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404–4408.
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089–1099.
Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006;79:639–651.
Zlotnik A. Chemokines and cancer. Int J Cancer 2006;119:2026–2029.
Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 2000;6:2735–2740.
Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci 2003;94:735–740.
Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152:93–100.
Kitadai Y, Takahashi Y, Haruma K, Naka K, Sumii K, Yokozaki H, et al. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 1999;81:647–653.
Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, Tsujimoto H, et al. Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 2008;122:2535–2541.
Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, et al. Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 2008;97:445–450.
Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998;220:1–17.
Sanz ML, Subira ML, Oehling A, Hernandez JL, Zornoza G. Immunologic study of carcinoma of the digestive tract. Effects of the tumor stage. I. Cellular immunity in the preoperative period. Allergol Immunopathol (Madr) 1982;10:33–42.
Jang TJ. The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract 2009;206:34–38.
Takagi A, Kamiya S, Koga Y, Ohta U, Kobayashi H, Shirai T, et al. Analysis of interleukin-8 secretion induced by Helicobacter pylori from the gastric epithelial cell line MKN45: a mechanism independent of the intensity of cytotoxicity. J Gastroenterol Hepatol 1997;12:368–372.
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–274.
Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003;3:1061–1071.
Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451–462.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsujimoto, H., Ono, S., Ichikura, T. et al. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?. Gastric Cancer 13, 212–221 (2010). https://doi.org/10.1007/s10120-010-0568-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-010-0568-x